tbuckley/cabot-search huggingface dataset:
PTH-005 Does having a delayed transit time influence outcome in chronic constipation?
Authors: U Khan, M Kipling, D Rowley-Conwy, J S Varma, Y Yiannakou
Journal: Gut (2010)

<h3>Introduction</h3> It is a common practice to subclassify patients with chronic constipation (CC) as having slow or normal transit using radio-opaque marker studies. However, the procedure has never been validated for construct validity and shows poor responsiveness. Recent reports have shown no correlation with symptoms or quality of life1; there is no correlation between transit and faecal loading2; and little value in assessing segmental transit3. Even so, perhaps it would be valuable in predicting outcome. The aim of this study was to assess outcome in patients with CC who had undergone a transit study. <h3>Methods</h3> The case notes of consecutive follow-up patients attending a specialist constipation clinic were surveyed. Patients for the study group were selected on the basis of fulfilling the Rome III criteria for chronic constipation (FC or IBS-C) and having colonic transit measured at the first clinic assessment. This was done using a validated radio-opaque marker technique. Details of treatments were recorded together with demographic details. Patients were divided into two groups depending on the type of treatment required to stabilise symptoms (conservative=laxatives, biofeedback, rectal irrigation; surgical=SNS, rectocoele repair, ACE, stoma, colectomy). Paired student t-test was used to calculate the difference between the colonic transit times of the two groups. Subject were divided into patients with slow transit constipation (STC) (&gt;45 markers retained) and normal transit constipation (NTC). The significance of treatments provided in each group was calculated using Fisher9s exact test. <h3>Results</h3> 148 patients were included, aged 18–72 years (mean 42.2 years). There were 22 men and 126 women. 79(53%) patients were satisfactorily managed with conservative treatment and 69 (46%) required surgical treatment. The mean transit time for conservative group was 56.13 h (SD 18.10) vs 55.14 h (SD18.32) for the surgical group. Paired t test did not demonstrate any differences between the transit times of the two groups (two-tailed p value 0.4761). There were 108 patients with STC and 40 with NTC. 53/108 (49%) had biofeedback in STC group whereas 16/40 (40%) in NTC group underwent biofeedback. There were no differences between STC and NTC groups (p value 0.3581). <h3>Conclusion</h3> There is no evidence from these data that transit times influence outcome. The use of slow transit to determine therapy has never been proven and further work is required to justify the validity of subclassification based on transit.
A Quantitative Study on Normal P sE Loop of Vectorcardiogram and P Wave of Scalar Electrocardiogram by Frank Lead System
Authors: Kazuhiko Hori
Journal: Circulation (1967)

The vectorcardiogram has been generally used not only for clinical diagnosis of heart disease but also for understanding of electrical activity of the heart. The informations sup-plied from various parameters as to the spatial vectors were contained sufficiently in vector-cardiogram projected to three planes consisted of frontal, horizontal, and left sagittal planes, whereas the informations as to the time parameters may not be sufficiently contained in these planes. Therefore, in addition to the analysis of vector loop itself, quantitative analysis of X, Y and Z leads scalar electro-cardiogram is also desirable in order to provide the informations of time parameters. The main problem of quantitative study in vectorcardiogram has been focussed to analysis of QRS SE^^^ and T SE^^^ loops. However, vector-cardiographic study of P SE Ioop has been re-ported only a few. Moreover, those reports were almost limited to the study by the cube system. Provided the informations obtained from analysing various pararneters upon P SE loop are added to those from QRS SE and T SE Ioops diagnosis of heart disease by vector-cardiogram will be made more accurately. In this paper, P SE lopofvectorcardiogram and P wave of scalar electrocardiogram by Frank lead system were recorded from normal adults and were analysed. The material was divided into two groups consisting of the nor-mal young adults and the normal aged adults and the age trend was discussed. Materials and Methods Eighty-nine normal young male adults ranged from 17 to 36 years (mean 26.4 years) and 33 normal aged male adults ranged from 40 to 70 years (mean 52.9 years) were selected, totaling 122 cases. Young adults were arbitrarily selected from the office personnel of Nagoya University Hospital who had had roentogenographic and physical examinations and were presumed free from pulmonary and cardiovascular diseases. Aged adults were select-ed from the subjects who had had thorough examinations containing roentogenographic and physical examinations and were presumed free from not only pulmonary and cardiovascular diseases but central nervous system disorders, metabolic and deficiency diseases. Those who had displayed abnormalities of QRS complex, ST-T changes, supraventricular arrhythmia, bradycardia less than 60/min and tachycardia more than 90/min in standard 12 lead ECG were excluded from the both groups.
Simultaneous determination of 14 active constituents of Shengjiang Xiexin decoction using ultrafast liquid chromatography coupled with electrospray ionization tandem mass spectrometry
Authors: Gang Peng, Huanyu Guan, Xiaoming Wang, Yue Shi
Journal: Acta Pharmaceutica Sinica B (2016)

An effective herbal medicinal prescription of Shengjiang Xiexin decoction (SXD) was used in treating the inflammatory bowel disease in clinic. In this study, an ultrafast liquid chromatography-tandem mass spectrometry (UFLC-MS/MS) method was developed to separate and to simultaneously determine 14 major active ingredients in SXD. Chromatographic separation was successfully accomplished on an Acquity BEH C18 (100 mm×2.1 mm, 1.7 μm) column using gradient elution with 0.1% (v/v) formic acid water (A) and 0.1% (v/v) formic acid in methanol (B). Negative and positive electrospray ionization tandem mass spectrometry was used to detect the 14 analytes using its selective reaction monitoring (SRM) mode. A good linear regression relationship for each analyte was obtained over the range from 3.88 ng/mL to 4080 ng/mL. The precision was evaluated by intra- and inter-day assays with a relative standard deviation (RSD) of less than 6.25%. The recovery measured at three concentration levels varied from 98.72% to 103.47%. The overall limits of quantification (LOQ) ranged from 2.05 ng/mL to 4.72 ng/mL. The method was successfully implemented in the qualitative and quantitative analyses of the 14 chemical constituents in SXD. The results showed that the developed UFLC-MS/MS method was linear and accurate. The method could be used reliably as a quality control method for SXD.
Postoperative Radiotherapy in Completely Resected Stage II and III Thymoma: How to Translate the Potential Survival Benefit in the Setting of the Future Adoption of the IASLC-ITMIG TNM-Based Staging System
Authors: Clémence Basse, Claire Merveilleux du Vignaux, Nicolas Girard
Journal: Journal of Thoracic Oncology (2016)
EphA3 Kinase Is Constitutively Activated in Chronic Myeloid Leukaemia during Progression to Accelerated and Blast Crisis and It Could Represent a New Molecular Target.
Authors: Daniela Cilloni, Francesca Arruga, Sonia Carturan, Francesca Messa, Monica Pradotto, Ilaria Defilippi, Marisa Pautasso, Ilaria Iacobucci, Giovanni Martinelli, Enrico Bracco, Thea Kalebic, Martin Lackmann, Giuseppe Saglio
Journal: Blood (2008)
Troponin Assessment in Heart Failure With Preserved Ejection Fraction
Authors: Gabriel Sayer, Nir Uriel
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
CD117 Expression Is a Poor Prognostic Factor (PF) for Progression Free Survival (PFS) and Freedom from Progression (FFP) in Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML).
Authors: Wael Saber, Rony Abou-Jawde, Eric Hsi, Tao Jin, Matt Kalaycio, Ronald Sobecks, Mikkael Sekeres, Brad Pohlman, Barbara L. Tripp, Anjali Advani
Journal: Blood (2005)
Are there differences in chemotherapy (CT) administration and outcomes in elderly patients (pts) diagnosed with colorectal cancer (CRC)?
Authors: R. Sehgal, C. E. Krug, J. Reifer, M. Tria Tirona, W. G. Douglas, P. Edwards, T. W. Gress
Journal: Journal of Clinical Oncology (2011)

557 Background: CRC is the third most common cancer in men and women in the United States. The median age at diagnosis is 70 years (yrs). Controversy exists in the literature regarding benefit from CT in elderly pts with CRC. We performed a retrospective study to evaluate CT rate and its benefit in different age groups of pts with CRC. Methods: Data on pts diagnosed with CRC from 1993-2008 were collected from the Cancer Information Resource File. Complete data on age, gender, stage, tumor characteristics, treatment, and overall survival (OS) were available on 32,177 pts and were analyzed by age in four categories: &lt; 50, 50-69, 70-79, and ≥ 80 yrs. Results: Of 32,177 pts, 7% were &lt; 50, 35% were 50-69, 32% were 70-78, and 26% were ≥ 80 yrs. The table reports pt demographics, median OS (MOS) by age and stage, and rates of CT by age and stage. As reported in the table, use of CT declined with advancing age, regardless of stage. Multivariate Cox regression analysis simultaneously adjusted for age at diagnosis, gender, race, stage, and grade revealed that CT was associated with reduced mortality in all age categories: &lt; 50 yrs, HR 0.75; 50-69, HR 0.61; 70-79, HR 0.53; and ≥ 80, HR 0.55 (all p &lt; 0.01). Conclusions: Older pts receive CT less frequently than younger pts. The use of CT in the elderly was associated with a reduced mortality, similar to that seen in younger pts. Younger pts were more likely to present with stage IV disease when compared to the elderly. Randomized, prospective trials are required to explore the differences noted. [Table: see text] No significant financial relationships to disclose.
sFRP-1: A functional prognostic marker for gastric cancer?
Authors: C. J. Moran, P. S. Ray, S. P. Bagaria, Y. Qu, A. J. Fleisig, M. Sim, R. R. Turner, X. Cui
Journal: Journal of Clinical Oncology (2011)

37 Background: Despite being a leading cause of cancer-related death world wide, gastric adenocarcinoma (GA) lacks distinctive biomarkers and targeted therapies. Underexpression of the E-cadherin gene in GA is associated with an aggressive phenotype and a poor prognosis but the mechanisms of this difference are poorly understood. Developing effective therapies for GA requires identification of critical functional markers and deeper understanding of its pathophysiology. Methods: Unsupervised hierarchical clustering analysis of a publicly available 230-sample GA microarray dataset identified a prominent cluster (21.7%) associated with underexpression of E-cadherin and overexpression of a Wnt-family protein: secreted frizzled-related protein 1 (sFRP-1). Archival GA specimens were then assessed for the expression of sFRP-1 by immunohistochemistry. Prognostic significance was assessed using univariate and multivariate analyses. GA cell lines transfected with sFRP-1 were used to determine the role of sFRP-1 in gastric cancer. Results: 85 patients with GA underwent surgery with curative intent; 39 stained positive for sFRP-1 (46%). In this positive group, sFRP-1 staining was focal; was commonly found on the leading edge of the infiltrating tumor mass; and was not restricted to one histopathologic group, grade, or clinical stage. On univariate analysis T stage, nodal involvement, pathologic stage, nuclear grade, E-cadherin status and sFRP-1 status were predictive of overall survival. In a multivariate model, T stage (p &lt; 0.001), nuclear grade (p &lt; 0.001), E-cadherin status (p = 0.031) and sFRP-1 status (p = 0.0097) were predictive of overall survival. Overexpression of sFRP-1 in GA cell lines induced mesenchymal phenotype, enhanced growth and stem cell-like properties. sFRP-1 also attenuated Wnt signaling and E-cadherin expression, but potentiated Notch and Hedgehog signaling known to be involved in GA progression. These findings suggest a Wnt-independent mechanism mediated by sFRP-1. Conclusions: The aggressive biological subtype of gastric cancer may be linked to overexpression of sFRP-1. Our findings identify sFRP-1 as a functional prognostic biomarker for gastric cancer, which may serve as a potential therapeutic target. No significant financial relationships to disclose.
Neuromedin U: A potential predictive biomarker for HER2-targeted drugs.
Authors: Sweta Rani, Serena Germano, Stephen F. Madden, Claire Corcoran, Susan Breslin, Neil A. O'Brien, Martina McDermott, Brigid Browne, Norma O'Donovan, John Crown, Lorraine O'Driscoll
Journal: Journal of Clinical Oncology (2012)

617 Background: Not all HER2-positive breast cancer patients respond to HER2-targeted drugs and some, who initially respond, subsequently relapse. There is a need to identify biomarkers for improved patient selection. Here we aimed to identify gene expression changes associated with response to HER2-targeted drugs. Methods: To identify mRNA changes associated with resistance, whole genome microarrays were used to profile conditioned medium (CM) from HER2-positive cell lines (SKBR3, HCC1954) and their lapatinib (L)-resistant variants (SKBR3-L R , HCC1954-L R ). Neuromedin U (NmU) over-expression, identified in this way, was confirmed in the L-resistant cells and corresponding CM by qPCR and ELISA. Pooled data from 21 published expression datasets (n=3489 patients) was mined to relate NmU mRNA to tumour subtype and patients' outcome. NmU cDNA and siRNAs were used to over-express and knock-down expression of NmU, respectively, prior to assessing it’s association with response to L, Trastuzumab (T) and Neratinib (N). Results: Analysis of the tumour data showed NmU expression to be particularly associated with poor outcome for patients with HER2-positive tumours (p=0.000005). In cell lines, we identified NmU mRNA and protein to be at significantly higher levels in L-resistant cells and corresponding CM, compared to that of L-sensitive SKBR3 and HCC1954. This trend was observed for T-resistant and N-resistant SKBR3 cells (SKBR3 T , SKBR3 N ) and their CM, compared to sensitive parent SKBR3 cells and CM. NmU cDNA over-expression in SKBR3 and HCC1954 increased resistance to L, T and N. Knock-down of NmU endogenous levels in SKBR3-L R and innately L-resistant MDA-MB-361 and T47D sensitised these cells to L, T and N. Further analysis of our NmU over-expressing and knock-down cells indicated NmU to also be associated with increased motility, invasion and anoikis resistance. Conclusions: NmU expression is prognostic of poor outcome in HER2-positive breast tumours. In cell line models, NmU over-expression is associated with resistance to L, T and N. Taken together, we propose NmU as a possible prognostic and predictive biomarker for HER2-positive cancers, with potential also as a co-target to help circumvent resistance to these drugs. [SFI: 08/SRC/B1410]
Real-time in vivo imaging of p16<sup>Ink4a</sup>reveals cross talk with p53
Authors: Kimi Yamakoshi, Akiko Takahashi, Fumiko Hirota, Rika Nakayama, Naozumi Ishimaru, Yoshiaki Kubo, David J. Mann, Masako Ohmura, Atsushi Hirao, Hideyuki Saya, Seiji Arase, Yoshio Hayashi, Kazuki Nakao, Mitsuru Matsumoto, Naoko Ohtani, Eiji Hara
Journal: The Journal of Experimental Medicine (2009)
Abstract 3760: Modeling spatial tumor growth as seen in clinical and radiological observations
Authors: Louise Viger, Clément Draghi, Fabrice Denis, Christophe Letellier
Journal: Cancer Research (2015)

Abstract Aim: Predicting tumour growth is a key issue in oncology for which correctly understanding underlying mechanisms is required. In order to do that, we developed a spatio-temporal mathematical model at tissue level for tumorigenesis. Our model is based on a set of four differential equations describing interactions between host, immune, tumour and endothelial cells that we recently developed for a single site. This model is spontaneously able to reproduce angiogenic switch and metastatic phenotype. Method: The present work is devoted to an extension onto a spatial two-dimensional Euclidean grid in which each site corresponds to approximatively ten thousand square micrometers and contains about one hundred cells. Only tumour cells can diffuse from one site to one of its eight nearest neighbors, thus corresponding to a partial differential equation with an isotropic Laplacian operator for tumour cell diffusion. Initial conditions are such as a single site located in the center of the grid contains tumour cells (all the other are tumour cells free). The tumour growth is thus obtained by integrating the differential equations using a fourth-order Runge-Kutta scheme. Results: Since we explicitly considered endothelial cells, our simulations can reproduce avascular as well as vascular tumour growth. We thus obtained round tumour until its diameter reaches two millimeters. Larger tumours are progressively deformed according to the nutrient gradient in the tissue: quiescent and necrotic zones are thus obtained as a function of tumour radius and micro-environment. Shaping our grid for reproducing lung anatomic, we were able to reproduce tumour growth constrained by the presence of anatomical structures such as bronchi. Conclusion: The structure of the so-obtained tumour is equivalent to those observed in patient using diagnosis imaging; our spatio-temporal model for tumour growth thus provides tumour growth in agreement with clinical and radiological observations. Citation Format: Louise Viger, Clément Draghi, Fabrice Denis, Christophe Letellier. Modeling spatial tumor growth as seen in clinical and radiological observations. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3760. doi:10.1158/1538-7445.AM2015-3760
Heavy/Light Chain Quantification Identifies Clonal Plasma Cell Disease in Patients with AL Amyloidosis and Normal Serum Free Light Chain Ratio
Authors: Tatiana Prokaeva, Brian Spencer, Fangui Sun, Nathaniel McConnell, Richard M O'hara, David C Seldin, Lawreen Connors, Vaishali Sanchorawala
Journal: Blood (2015)
Abstract 1349: Tim-3/galectin-9 interaction might be associated with the immunosuppression of gastrointestinal stromal tumor (GIST)
Authors: HIDEO KOMITA, Sigeo Koido, Hisao Tajiri, Masafumi Suzuki, Sadamu Homma
Journal: Cancer Research (2015)

Abstract Purpose: Although GIST shows high expression of Wilms’ Tumor 1 (WT1) and might be potentially immunogenic, there are no evidences that antitumor immunity suppresses GIST development. Elucidation of the mechanism of the immunosuppression of GIST might contribute to the establishment of the immunotherapy against GIST. Methods: Nineteen GIST tissue samples were evaluated for the expression of various tumor-associated antigens, MHC class I, immune check point molecules and the infiltration of immune cells by immunohistochemistry. Tumor infiltrating lymphocytes (TILs) from freshly resected GIST tissues were analyzed for WT1 tetramer assay. Results: All GIST tissues showed diffuse WT1 expression but not GP-100, NY-Eso1, Melan A and MAGEA4. They all expressed MHC class I and WT1 tetramer positive CD8+T cells were found in TILs from some GIST tissues. Seven GIST tissues showed marked CD8+ T cell infiltration and the infiltration of CD8+T cells and NK cells was strongly correlated. However, all the immune cells infiltrated into GIST tissues were CD69 negative inactivated cells. Although PD-1/PD-L1 expression was not seen in GIST tissues, galectin-9 was expressed in tumor cells and Tim-3 was expressed on NK cells but not CD8+T cells in all the GIST tissues. Conclusions: Galectin-9 on tumor cells and Tim-3 on infiltrated NK cells might be associated with the immunosuppression of GIST. Citation Format: HIDEO KOMITA, Sigeo Koido, Hisao Tajiri, Masafumi Suzuki, Sadamu Homma. Tim-3/galectin-9 interaction might be associated with the immunosuppression of gastrointestinal stromal tumor (GIST). [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1349. doi:10.1158/1538-7445.AM2015-1349